Hilton Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Hilton Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-38	Closed	-$12K	–	333
2019 Q2	$12K	Hold	38	–	–	﹤0.01%	299
2019 Q1	$16K	Hold	38	–	–	﹤0.01%	285
2018 Q4	$14K	Hold	38	–	–	﹤0.01%	249
2018 Q3	$15K	Hold	38	–	–	﹤0.01%	253
2018 Q2	$13K	Buy	+38	New	+$11.9K	﹤0.01%	286

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Hilton Capital Management's REGN Position: Q3 2019 in Review

Hilton Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2019, closing a stake of 38 shares — an estimated $12K sold.

Hilton Capital Management first reported a position in REGN in Q2 2018 and held it in 5 quarters. The position peaked at $16K in Q1 2019. 632 funds tracked by Wall St. Rank hold REGN as of Q3 2019.

Hilton Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Hilton Capital Management sold 38 Regeneron Pharmaceuticals shares in Q3 2019, an estimated $12K.
Hilton Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2018 and held it in 5 quarters.
Hilton Capital Management's Regeneron Pharmaceuticals position peaked at $16K in Q1 2019.
632 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2019.

Based on Hilton Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.